Journal
Blood Advances
Publication Date
2-24-2026
Volume
10
Issue
4
First Page
1372
Last Page
1380
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2025018527
Rights and Permissions
Wang Y, Larson MC, Hwang SR, Villa D, Kugathasan L, Kumar A, Joseph A, Brooks TR, Hill BT, Bond DA, Maddocks KJ, Nizamuddin IA, Kahl BS, Danilov A, Argao C, Ruan J, Ryan CE, Merryman RW, Grover NS, Khan NB, Ouchveridze E, Tun AM, Ayyappan S, Mou E, Pongas GN, Lossos IS, Harris ZI, Munoz JL, Young P, Portell CA, Baidoun F, Alhaj Moustafa M, Reagan PM, Banaszak LG, Pophali PA, Velayati A, Greenwell IB, Gerber D, Jain P, Wang ML, Narkhede MS, Mehta A, Stack AC, Messmer MR, Bhansali RS, Barta SK, Moyo TK, Ghosh N, Kamdar MK, Anna J, Stanisic AV, Karmali R, Maurer MJ, Cerhan JR, Cohen JB, Martin P. Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma. Blood Adv. 2026 Feb 24;10(4):1372-1380. doi: 10.1182/bloodadvances.2025018527. © 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Wang, Yucai; Nizamuddin, Imran A; Kahl, Brad S; and et al., "Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphoma." Blood Advances. 10, 4. 1372 - 1380. (2026).
https://digitalcommons.wustl.edu/oa_4/6514
Additional Links
Supplemental material is available for this article at publisher site.
